From Invasive Implantable Devices to Non-invasive Therapies: Benchmarking Innovation that Shapes the Future of Neuropsychiatric Treatment
Keeping Up with Transformative Forces in Neuromodulation
The neuromodulation devices landscape is advancing rapidly as the global burden of neuropsychiatric disorders intensifies.
This is where Frost & Sullivan’s competitive benchmarking framework enables technology leaders and healthcare innovators to identify what drives differentiation, clinical impact, and growth leadership in the evolving neuromodulation landscape.
Download Now
| Growth Driver | Growth Analytics | Timeline |
|---|---|---|
| Rising Mental Health | 1 in 8 people globally experience mental health disorders such as anxiety, depression, PTSD, or schizophrenia | Current |
| Mainstream Adoption of Neuromodulation | Technologies like Transcranial Magnetic Stimulation (TMS) and Deep Brain Stimulation (DBS) are now standard care options | 2024 – 2026 |
| Emerging Modalities | Growing focus on Transcranial Electrical Stimulation (tES), Transcutaneous Afferent Patterned Stimulation (TAPS), and Responsive Neurostimulation (RNS) | 2025 - 2027 |
| Non-invasive & Wearable Devices | Compact, affordable, and patient-friendly solutions gaining traction for home-based use | 2025 and beyond |
How will your organization adapt to these transformative forces shaping brain health innovation?
Ways for Industry Leaders to Differentiate Themselves
To accelerate innovation and strengthen growth pipelines, neuromodulation device manufacturers and digital health companies are focusing on:
AI-driven Personalization
Integrating artificial intelligence and data analytics to optimize stimulation protocols and predict patient outcomes.
Partnership Ecosystems
Collaborating with regulators (such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)), payers, and technology partners to ensure safe, effective, and reimbursable solutions.
Accessible
Therapies
Designing cost-effective, portable devices that expand access to underserved regions and enable continuous, home-based neuromodulation treatment.
Evidence-based Differentiation
Generating rigorous clinical data on efficacy, safety, and adaptability to position neuromodulation as a validated alternative to pharmacotherapy.
Which collaborations will help your organization lead in the next phase of neuromodulation growth?
Download now for detailed competitive intelligence on companies to watch, technology differentiation, and growth opportunities in the evolving neuromodulation ecosystem
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on store.frost.com.
*$1,000 honorarium is subject to eligibility
